Intelligence · Clinical Pipeline
Aligos Therapeutics Pipeline
All ClinicalTrials.gov programs at Aligos Therapeutics — phase, modality, and trial IDs.
- Programs
- 11
Quick answer
Aligos Therapeutics has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
ALG-000184
Aligos Therapeutics
Chronic Hepatitis B
1 trial -
ALG-010133
Aligos Therapeutics
Chronic Hepatitis B
1 trial -
ALG-020572
Aligos Therapeutics
Chronic Hepatitis B
1 trial -
ALG-055009
Aligos Therapeutics
Healthy Volunteer Study
1 trial -
ALG-055009
Aligos Therapeutics
NASH - Nonalcoholic Steatohepatitis
1 trial -
ALG-097558
Aligos Therapeutics
COVID-19
3 trials -
ALG-125755
Aligos Therapeutics
Chronic Hepatitis B
1 trial -
Atorvastatin
Aligos Therapeutics
Healthy Volunteers
1 trial -
Carbamazepine
Aligos Therapeutics
Healthy Volunteer
1 trial -
Pevifoscorvir Sodium (ALG-000184)
Aligos Therapeutics
Chronic Hepaititis B Infections
1 trial -
Pevifoscorvir Sodium (ALG-000184)
Aligos Therapeutics
Chronic Hepatitis B Infection
1 trial
Frequently asked questions
How many pipeline programs does Aligos Therapeutics have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs